Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Doug Drysdale

Recent news which mentions Doug Drysdale

Psychedelics Policy Is Shifting In Washington: Here's What One Biotech CEO Sees Coming
Tickers CYBN
Tags Exclusives Benzinga Matthew Zorn
From Benzinga
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Tickers CYBN
Tags Cannabis Benzinga Doug Drysdale
From Benzinga
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
Tickers CYBN
Tags CYBN Earnings financial results
From Benzinga
Cybin Stock Down On Laying Off 15% Of Workforce As Part Of A Streamlining Clinical Alignment
Tickers CYBN
Tags Doug Drysdale Markets Cannabis
From Benzinga
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Tickers CYBN DMT
Tags News Cybin DMT
From Benzinga
Cybin Acquires Exclusive License To Mindset Pharma's Tryptamine Compounds Family
Tickers CYBN MSSTF
Tags Penny Stocks Doug Drysdale Benzinga
From Benzinga
Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression
Tickers CYBN
Tags Cybin Inc/ CYB003 CYBN
From Benzinga
BREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
Tickers CYBN DEA MDD
Tags CYBN Psychedelics Health Care
From Benzinga
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
Tickers CYBN
Tags Market News News FDA Approval
From Benzinga
Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements
Tickers CYBN
Tags Psychedelics CYBN Earnings
From Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
Tickers CYBN TWTR
Tags Elon Musk Penny Stocks Doug Drysdale
From Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Tickers CYBE CYBN ENTBF
Tags Markets General Global
From Benzinga
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
Tickers CYBN
Tags Market News FDA Approval News
From Benzinga
Cybin's Major Depressive Disorder Treatment Trials Continue With Clinilabs Drug Development Corp
Tickers CYBN
Tags Cybin News Market News
From Benzinga
EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics
Tickers CYBN DMT PCC
Tags CYBN Events Psychedelics
From Benzinga
A Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our Speakers
Tickers AGN CYBN PTX
Tags Psychedelics Benzinga Psychedelics Capital Conference CYBN
From Benzinga
Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event
Tickers CYBN FTRP MMDCF PSYC
Tags Cannabis Psychedelics Event Benzinga
From Benzinga
Cybin Obtains U.S. Patent For Is Proprietary Compound Deuterated DMT Aimed At Treating Anxiety Disorders
Tickers CYBN
Tags CYBN News Market News
From Benzinga
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
Tickers CYBN FTRP WSNAF
Tags FTRP Dr/ Nathan Bryson WSNAF
From Benzinga
Why Cybin Shares Are Rising
Tickers CYBN
Tags Market News why it's moving Movers
From Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
Tickers CYBN
Tags Market News Earnings Cybin
From Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
Tickers CYBN
Tags News Psychedelics Therapy Cybin
From Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Tickers CMPS CYBN FLHLF NMLSF
Tags CMPS RVVTF CYBN
From Benzinga
Cybin Becomes First Psychedelics Company On The NYSE: CEO Explains Everything You Need To Know
Tickers CLXPF CMPS GBNH
Tags Benzinga Cannabis Markets
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.